Navigation Links
Liver-cell transplants show promise in reversing genetic disease affecting liver and lungs
Date:4/22/2011

April 21, 2011 -- (Bronx, NY) -- Transplanting cells from healthy adult livers may work in treating a genetic liver-lung disorder that affects millions of people worldwide, according to an animal study in the April 18 online edition of the Journal of Clinical Investigation. Jayanta Roy-Chowdhury, M.D. , professor of medicine and of genetics at Albert Einstein College of Medicine of Yeshiva University, is the study's senior author.

The genetic disorder, alpha-1 antitrypsin (AAT) deficiency, is the most common potentially lethal hereditary disease among Caucasians, affecting an estimated 100,000 people in the United States and 3.4 million people worldwide. AAT is a protein made by the liver that is essential for lung health. In AAT deficiency, the liver produces a misshapen form of AAT that cannot enter the bloodstream and instead gets stuck inside liver cells, causing two major problems:

  • AAT accumulates in the liver, leading to fibrosis (development of scar tissue) and liver failure;
  • Too little AAT reaches the lungs, where it's needed to rein in elastase, an enzyme produced by white blood cells. Elastase helps kill bacteria in the lungs, but uncontrolled elastase activity can damage lung tissue and lead to severe emphysema (chronic obstructive pulmonary disease).
  • In the study, Dr. Roy-Chowdhury and his colleagues tested cell therapy on transgenic mice whose liver cells (hepatocytes) had been engineered to produce mutant human AAT, resulting in liver fibrosis. When the mice were given infusions of hepatocytes harvested from the livers of healthy mice, the transplanted cells proliferated in the host liver, progressively replacing diseased hepatocytes. Most importantly, said Dr. Roy-Chowdhury, the transplanted cells reversed the fibrosis that had developed.

    Current therapy for AAT deficiency consists of life-long injections of a genetically engineered version of AAT called Prolastin. "This very expensive therapy slows progression of the lung disease in some patients but does not have any beneficial effect on the liver disease," said Dr. Roy-Chowdhury. The only other therapy for AAT deficiency is combined lung-liver transplantation, which is reserved for the sickest patients.

    "These promising results in animals indicate that it may be worthwhile to investigate the usefulness of hepatocyte transplantation for AAT deficiency as well as a variety of other inherited liver-based disorders," said Dr. Roy-Chowdhury.


    '/>"/>

    Contact: Kim Newman
    sciencenews@einstein.yu.edu
    718-430-3101
    Albert Einstein College of Medicine
    Source:Eurekalert

    Related medicine news :

    1. Internal Anthem Blue Cross/WellPoint Document: Only Patients Who Push Back Get Covered Out of State Liver Transplants
    2. Los Angeles Hair Transplant Cosmetic Surgeon Corrects Bad Hair Transplants With New Hair Restoration Method
    3. Kidney transplants: Expanding the pool of available organs
    4. Patients with treatment-resistant CLL respond positively to stem cell transplants
    5. Hispanics and Asians less likely to receive liver transplants
    6. Biosynthetic Corneas Show Promise in Transplants
    7. OHSU research suggests compound administered during some bone marrow transplants elevates risks
    8. Kidney Transplants for Elderly Double Over Decade
    9. HIV Patients Do Well After Kidney Transplants: Study
    10. 2 people receive kidney transplants in pilot program using CMU software
    11. Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
    (Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement earlier ... position. The former overall number one pick in the 2001 NFL Draft, to the ... the record for the most career rushing yards by a quarterback (6,109) and the ...
    (Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin ... of Education Research Award. The award honors scholars exemplary in their capacity to ... scholar who has demonstrated the capacity to deepen the public’s understanding and appreciation ...
    (Date:4/24/2017)... Seattle, Washington (PRWEB) , ... April 24, 2017 , ... ... T-Fal OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill ... than perhaps any other marketer in the last 25 years. , Now, due to ...
    (Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... that they are seeking public support to bring their novel lifesaving device for ... wearable device packed with medical-grade sensors, specially designed to read a child’s vital ...
    Breaking Medicine News(10 mins):
    (Date:4/18/2017)... Research and Markets has announced the addition ... their offering. ... devices market to grow at a CAGR of 6.35% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
    (Date:4/18/2017)... and BLOOMINGTON, Minn. , April ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, ... Lens"), today announced the signing of a three-year ... Lens will deploy a dedicated sales team to ... the U.S., primarily focused in 13 states in ...
    (Date:4/18/2017)... 2017 Research and Markets has announced ... Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023" ... ... revenues as well as growth in the number of unit ... to market participants that design and manufacture molecular imaging equipment. ...
    Breaking Medicine Technology: